Join
Live feed
·
PRReleasevia Quantisnow
Precision BioSciences Inc. logo

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

ByQuantisnow·Wall Street's wire, on your screen.
DTIL· Precision BioSciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DTIL (Precision BioSciences Inc.) and more on Quantisnow.